Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting

Clinical Therapeutics

Volumn 26, Issue 7, 2004, Pages 1149-1159

  Willey, Vincent J ^a   Bullano, Michael F ^a   Hauch, Ole ^b   Reynolds, Matthew ^b   Wygant, Gail ^b   Hoffman, Lauren ^c   Mayzell, George ^c   Spyropoulos, Alex C ^d  

^a HEALTHCORE INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Blue Cross Blue Shield of Florida   (United States)

^d LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

administrative claims data; outcomes; pulmonary embolism; retrospective; thromboembolism; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNATIONAL STANDARD UNIT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NEGATIVE FEEDBACK; PREVALENCE; PROTHROMBIN TIME; RANDOMIZATION; RECURRENT DISEASE; TREATMENT OUTCOME; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICAL RECORDS; MIDDLE AGED; PULMONARY EMBOLISM; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS; WARFARIN;

EID: 4344579743     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90187-7     Document Type: Article

References (49)

1. Murin S., Romano P.S., White R.H. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 88:2002;407-414
2. Silverstein M.D., Heit J.A., Mohr D.N., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med. 158:1998;585-593
3. Johnson M.S. Current strategies for the diagnosis of pulmonary embolus. J Vasc Intervent Radiol. 13:2002;13-23
4. Meignan M., Rosso J., Gauthier H., et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med. 160:2000;159-164
5. Spyropoulos A.C. Outpatient-based treatment protocols in the management of venous thromboembolic disease. Am J Manag Care. 6:2000;S1034-S1044
6. Ageno W. Treatment of venous thromboembolism. Int J Hematol. 76:(Suppl 2):2002;40-43
7. Da Silva M.S., Sobel M. Anticoagulants: To bleed or not to bleed, that is the question. Semin Vasc Surg. 15:2002;256-267
8. Haas S.K. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost. 28:2002;577-584
9. Zierler B.K., Meissner M.H., Cain K., Strandness D.E. Jr. A survey of physicians' knowledge and management of venous thromboembolism. Vasc Endovascular Surg. 36:2002;367-375
10. Cook D., McMullin J., Hodder R., et al. Prevention and diagnosis of venous thromboembolism in critically ill patients: A Canadian survey. Crit Care. 5:2001;336-342
11. Spyropoulos A.C., Hurley J.S., Ciesla G.N., de Lissovoy G. Management of acute proximal deep vein thrombosis: Pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest. 122:2002;108-114
12. Tillman D.J., Charland S.L., Witt D.M. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med. 160:2000;2926-2932
13. Harrison L., McGinnis J., Crowther M., et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med. 158:1998;2001-2003
14. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 334:1996;677-681
15. Prandoni P., Lensing A.W., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 125:1996;1-7
16. Wells P.S., Kovacs M.J., Bormanis J., et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch Intern Med. 158:1998;1809-1812
17. Brandjes D.P., Heijboer H., Buller H.R., et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 327:1992;1485-1489
18. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 337:1997;657-662
19. Go A.S., Hylek E.M., Chang Y., et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA. 290:2003;2685-2692
20. Evans A., Kalra L. Are the results of randomized clinical trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med. 161:2001;1443-1447
21. Evans A., Perez I., Yu G., Kalra L. Secondary stroke prevention in atrial fibrillation: Lessons from clinical practice. Stroke. 31:2000;2106
22. Kalra L., Yu G., Perez I., et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 320:2000;1236-1239
23. Gage B.F., Boechler M., Doggette A.L., et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 31:2003;822-827
24. Caro J.J., Flegel K.M., Orejuela M.E., et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: Effectiveness in actual practice. published correction appears in CMAJ. 162:2000;973
25. Caro J.J., Flegel K.M., Orejuela M.E., et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: Effectiveness in actual practice. CMAJ. 161:1999;493-497
26. Aronow W.S., Ahn C., Kronzon I., Gutstein H. Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc. 47:1999;366-368
27. Goldenberg G.M., Silverstone A., Rangu S., Leventer S.L. Outcomes of long-term anticoagulation in frail elderly patients with atrial fibrillation. Clin Drug Invest. 17:1999;483-488
28. Gottlieb L.K., Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 154:1994;1945-1953
29. Barritt D.W., Jordan S.C. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1:1960;1309-1312
30. Sachdev G.P., Ohlrogge K.D., Johnson C.L. Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: Outpatient management for adults. 3rd ed Am J Health Syst Pharm. 56:1999;1505-1514
31. Hirsh J., Dalen J., Anderson D.R., et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119:(Suppl 1):2001;8S-21S
32. Ginsberg J.S. Management of venous thromboembolism. N Engl J Med. 335:1996;1816-1828
33. Dolovich L.R., Ginsberg J.S., Douketis J.D., et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 160:2000;181-188
34. Gould M.K., Dembitzer A.D., Sanders G.D., Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 130:1999;789-799
35. Rodger M., Bredeson C., Wells P.S., et al. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin treatment of deep vein thrombosis. CMAJ. 159:1998;931-938
36. Hyers T.M., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 119:2001;176S-193S
37. Schneeweiss S., Seeger J.D., Maclure M., et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 154:2001;854-864
38. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 69:1993;236-239
39. Gleason J. Improved confidence intervals for binomial proportions. Stat Technical Bull. 9:1999;208-211
40. Gardner W., Mulvey E.P., Shaw E.C. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull. 118:1995;393-404
41. Moulton B.R. Random group effects and the precision of regression estimates. J Econometrics. 32:1986;385-397
42. Raftery A. Bayesian model selection in social research. Marsden P.V. Sociological Methodology. 1996;111-196 Blackwells, Cambridge, Mass
43. Alpert J.S., Smith R., Carlson J., et al. Mortality in patients treated for pulmonary embolism. JAMA. 236:1976;1477-1480
44. Kernohan R.J., Todd C. Heparin therapy in thromboembolic disease. Lancet. 1:1966;621-623
45. White R.H., Zhou H., Romano P.S. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med. 158:1998;1005-1010
46. Koopman M.M., Prandoni P., Piovella F., et al. Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. [published correction appears in N Engl J Med. 1997;337:1251] N Engl J Med. 334:1996;682-687
47. Hutten B.A., Prins M.H., Gent M., et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol. 18:2000;3078-3083
48. Casey M., Hanley K. A measurement of the efficacy of anticoagulation monitoring in a general practice based setting. Ir Med J. 94:2001;245-246
49. Armstrong E.P., Manuchehri F. Ambulatory care databases for managed care organizations. Am J Health Syst Pharm. 54:1997;1973-1983